Drug repurposing

Drug Repurposing and
Discovery Services

“In a drug target validation effort, Delta4 helped generate new insights regarding the clinical utility of a family of proteins. The Delta4 team members are highly competent in big data network analyses both from the disease side and from the drug product and pharmacology side. Their methodology of marrying one with the other led us to new intellectual property. In addition to their scientific strengths, the team also comes across as very forthcoming and adaptive to customer needs. Their reporting is thorough and to the point. We highly recommend Delta4 as an AI partner for drug discovery and development.”

– Johan Häggblad, PhD, Chief Scientific Officer at Calliditas Therapeutics.

About us

What We Do

At Delta4, we are leaders in all aspects of AI-enabled drug repurposing and indication expansion. We are committed to empowering scientists, clinicians, and drug developers to discover treatments for diseases, improve existing treatments, and make healthcare more efficient and effective for all. Our data-driven approach combines the power of Artificial Intelligence with the insights of experts in the field of drug repurposing to discover new uses and effectively expand indications for existing drugs.

Drug repurposing is the process of finding new therapeutic uses for existing drugs. This process can save companies time, money, and effort in the development of new treatments. The challenge, however, is that the process is complex and requires sophisticated algorithms to identify potential drug candidates.
Delta4 has invested heavily in developing Hyper-C, a comprehensive platform that enables drug discovery and repurposing. Our AI-enabled platform is designed to identify potential drug candidates and then rigorously assess their effectiveness.

We strive to provide our customers with the highest quality of service. We are constantly working to improve our platform and develop new algorithms that can uncover promising drug candidates faster and more accurately. We have a team of experienced professionals who are dedicated to helping our customers be successful in the drug repurposing process.

Our work

How We Can Help

Find or Expand Indications For Your Existing Drugs

Our AI-powered platform enables companies to quickly identify new therapeutic uses for existing drugs with known safety profiles and accelerate their development, approval, and commercialization.

Identify and rank disease-modifying drug targets

Hyper-C can rapidly identify drug targets which are essential for the development of safe and effective drugs. This helps to significantly reduce drug development time and cost by focusing on drug targets with the greatest potential to be effective.

Propose prognostic and predictive protein biomarkers

With our platform, researchers, pharmaceutical companies, and clinicians can identify potential biomarkers for various diseases and medical conditions. This gives them the ability to predict disease progression, identify prognostic indicators, and even personalize treatment plans.

Provide specific background info on a drug effect/side effect

Leveraging Hyper-C’s artificial intelligence-powered algorithms, we’re able to provide insights into how potential drug effects and side effects may interact with each other, allowing for safer and more effective treatments.

Repositioning Approaches

We believe that a comprehensive approach is the best way to uncover potential treatments. Our team is dedicated to leveraging cutting-edge computational drug repositioning approaches that can uncover novel treatments faster and more accurately than ever before. Delta4 employs more computational drug repositioning approaches than our competitors.

Network-Based

Network-based approaches leverage the power of data-driven drug discovery to uncover potential treatments by analyzing the physical, chemical, and biological properties of molecules. Our network-based approach utilizes a large array of datasets, such as genomic, proteomic, and metabolomic data, to evaluate the biological effects of molecules based on their chemical structure.

Target-Based

Target-based approaches focus on the specific proteins and receptors that are known to be involved in a disease. By analyzing the interactions between proteins, we can discover potential drugs that are effective in targeting a given protein.

Signature-Based

Signature-based approaches use gene expression signatures to identify drug targets. By analyzing gene expression data from disease models, we are able to uncover potential drug targets that may have a therapeutic effect on a particular condition.

Genetic Association Based

Genetic association-based approaches involve leveraging genetic data to identify novel therapies that may be effective for a particular disease. By considering the genetic variants that are associated with the disease, we can better understand the underlying mechanisms of the disease and identify potential drug therapies that may be effective.

Text-Mining Based

Our text mining-based approach uses natural language processing to identify potential drugs from the biomedical literature. By analyzing the text of scientific articles, we can uncover potential treatments that may not have been identified with other approaches.

Our Partners & Clients

At 4P-Pharma, our foundation is based on scientific rationale. Delta4 has provided us with this essential foundation for our co-development project, enabling us to start from the mechanism of action in the disease. This approach allows us to more accurately and quickly identify and validate therapeutic targets, making our drug development process more efficient and focused.

The Delta4 team members are highly competent in big data network analyses both from the disease side and from the drug product and pharmacology side. Their methodology of marrying one with the other led us to new intellectual property.

This innovative methodology has enabled us to identify therapeutic targets that have never been described before for specific indications.

Thanks to DELTA4, we have been able to speed up the selection of preclinical models, that will allow us to effectively prove the beneficial effects of those drug candidates.

Their reporting is thorough and to the point. We highly recommend Delta4 as an AI partner for drug discovery and development.

...allowing us to progress in bringing new drugs to patients suffering from serious, untreated diseases.

Streamlining Transparency and Cooperation

Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.

“Delta4’s AI-Powered Hyper-C Platform Uncovers New Drug Indications, Expanding Treatment Potential for Iguratimod” – As Featured on Scientist.com

Are you a member of Scientist.com? View Our Profile

Get Involved

Learn how you can contribute to the exciting work happening at Delta4

Careers

Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.

Investors

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.

Drug repurposing